Identification of T-cell epitopes in clotting factor IX and lack of tolerance in inbred mice

Journal of Thrombosis and Haemostasis

Volumn 1, Issue 1, 2003, Pages 95-102

  Greenwood, R ^a   Wang, B ^a   Midkiff, K ^a   White G C , ^a   Lin, H F ^a   Frelinger, J A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Factor IX; T cell epitope

Indexed keywords

BLOOD CLOTTING FACTOR 9; EPITOPE; IMMUNOGLOBULIN G; PEPTIDE FRAGMENT; RECOMBINANT PROTEIN;

AMINO ACID SEQUENCE; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BIOSYNTHESIS; C57BL MOUSE; CD4+ T LYMPHOCYTE; CROSS REACTION; GENETICS; HUMAN; IMMUNIZATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MOLECULAR GENETICS; MOUSE; MOUSE MUTANT; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CROSS REACTIONS; EPITOPES, T-LYMPHOCYTE; FACTOR IX; HUMANS; IMMUNE TOLERANCE; IMMUNIZATION; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 0141818963     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1046/j.1538-7836.2003.00001.x     Document Type: Article

References (19)

1. Giannelli F, Green PM, Sommer SS, Poonr M, Ludwig M, Schwaab R, et al. Haemophilia B: database of point mutations and short additions and deletions - eighth edition. Nucleic Acids Res 1998; 26: 265-8.
2. Fields PA, Kowalczyk DW, Arruda VR, Armstrong E, McCleland ML, Hagstrom JN, et al. Role of vector in activation of T cell subsets in immune responses against the secreted transgene product factor IX. Mol Ther 2000; 1: 225-35.
3. Singer ST, Addiego JE Jr, Reason DC, Lucas AH. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996; 76: 17-22.
4. Reding MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Key NS, et al. CD4+ T cell response to factor VIII in hemophilia A, acquired hemophilia, and healthy subjects. Thromb Haemost 1999; 82: 509-15.
5. Reding MT, Wu H, Krampf M, Okita DK, Diethelm-Okita BM, Christie BA, et al. Sensitization of CD4+ T cells to coagulation factor VIII. response in congenital and acquired hemophilia patients and in healthy subjects. Thromb Haemost 2000; 84: 643-52.
6. Burns J, Rosenzweig A, Zweiman B, Lisak RP. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 1983; 81: 435-40.
7. Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95: 1324-9.
8. Wu H, Reding M, Qian J, Okita DK, Parker E, Lollar P, et al. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85: 125-33.
9. Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW. A coagulation factor IX-deficient mouse model for human hemophilia B. Blood 1997; 90: 3962-6.
10. Wakeland E, Morel L, Achey K, Yui M, Longmate J. Speed congenics: a classic technique in the fast lane (relatively speaking). Immunol Today 1997; 18: 472-7.
11. Peterson DA, DiPaolo RJ, Kanagawa O, Unanue ER. Quantitative analysis of the T cell repertoire that escapes negative selection. Immunity 1999; 11: 453-62.
12. Orstavik KH, Miller CH. IgG subclass identification of inhibitors to factor IX in haemophilia B patients. Br J Haematol 1988; 68: 451-4.
13. Yip HC, Karulin AY, Tary-Lehmann M, Hesse MD, Radeke H, Heeger PS, et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol 1999; 162: 3942-9.
14. Windhagen A, Scholz C, Hollsberg P, Fukaura H, Sette A, Hafler DA. Modulation of cytokine patterns of human autoreactive T cell clones by a single amino acid substitution of their peptide ligand. Immunity 1995; 2: 373-80.
15. Constant SL, Bottomly K. Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. Annu Rev Immunol 1997; 15: 297-322.
16. Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophiliac with factor-VIII inhibitor, high responder. Lancet 1977; 2: 933.
17. DiMichele DM, Kroner BL. The North American Immune Tolerance Registry. Practices, outcomes and outcome predictors. Thromb Haemost 2002; 87: 52-7.
18. Liblau R, Tisch R, Bercovici N, McDevitt HO. Systemic antigen in the treatment of T-cell-mediated autoimmune diseases. Immunol Today 1997; 18: 599-604.
19. Fields PA, Arruda VR, Armstrong E, Chu K, Mingozzi F, Hagstrom JN, et al. Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9. Mol Ther 2001; 4: 201-10.